CBDual Biotechnology Corp. announces the completion of their new clinical trial center in southern California
March 02 2017 - 9:30AM
InvestorsHub NewsWire
Los Angeles, CA -- March 2, 2017 -- InvestorsHub
NewsWire -- CBDual Biotechnology Corp. (“CBDUAL”) announced today, the completion of the
company’s new clinical trial center in Southern
California.
CBDual’s new facility provides patients with
easy access to participate in clinical trials of new medical
cannabis medications, therapies and products. CBDual will
develop protocols to improve patient safety and data integrity in
clinical research trials in compliance with the
HIPAA.
The first scheduled trial will study the
medicinal and therapeutic effects of CBD on oral health. The study
anticipates between 1,000-2,000 patients and will test the effects
of different CBD based mouthwashes and
toothpastes.
CBDual has recently entered into a cross
licensing agreement with Cavitation Technologies, Inc (OTCQB:
CVAT; Berlin: WTC). This agreement covers intellectual property
involving the application of technology and patented processes to
produce high quality pharmaceutical grade cannabis materials with
increased bio-availability and increased shelf
life.
Dr. Greg Rubin, CEO of CBDual Biotechnology Corp.
previously commented, “The improvement of consumer and medical
products require the development of the best quality and
utilization of the most innovative technologies in order to achieve
ultimate results. The impact of the new clinical research brings
us one step closer to introducing our new products to the US
markets.”
Recent breakthroughs in Cannabinoid (CBD)
therapies and orally administered products prompt strong forecast
for 2017. The Hemp Business Journal estimated that the CBD market
will emerge as a $2.1 billion market in consumer sales by 2020.
That represents a 700% increase from 2016. According to the
National Institute on Drug Abuse, a number of studies have shown
that CBD is a non-psychoactive cannabinoid and has a wide range of
medical benefits, such as anti- inflammatory and anti-oxidant and
many other health related benefits.
About CBDual Biotechnology
Corp
CBDual Biotechnology is a privately held; US
based Biotechnology Company with a proprietary technology for
enhanced oral delivery of bioactive cannabinoids. This technology
promotes good gums health and overall dental health due to higher
effectiveness of the delivery methodology. Company was founded in
2016 and is headquartered in California with its R&D capability
in Israel and Ukraine..
Website: http://www.cbdual.com/
About Cavitation
Technologies, Inc.
Founded in 2007, the company designs
and manufactures state-of-the-art, flow-through, devices and
systems as well as develops processing technologies for use in
edible oil refining, renewable fuel production, expeditious
petroleum upgrading, algae oil extraction, alcoholic beverage
enhancement, water treatment and cannabidiol processing. As an
add-on to its existing neutralization systems, the company's
patented Nano Reactor™ allows refiners to significantly reduce both
processing costs and environmental impact, while also increasing
yield.
Website: http://www.ctinanotech.com/
Follow us on Twitter: https://twitter.com/ctinanotech
Like us on Facebook: https://www.facebook.com/ctinanotech
Forward Looking
Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements
regarding the anticipated installation and the timing of the
installation, our intent to continue to focus on research and
development, marketing and sales of our unique technology, our
belief that our company is positioned for accelerated growth and
the expected efforts to be made to enhance our shareholder's value.
These forward-looking statements are based largely on the Company's
expectations and are subject to a number of risks and
uncertainties, certain of which are beyond the Company's control.
Actual results could differ materially from these forward looking
statements as a result of a variety of factors including, among
others, the state of the economy, the competitive environment and
our ability to perform the installation as anticipated and other
factors described in our most recent Form 10-K and our other
filings with the SEC, including subsequent periodic reports on
Forms 10-Q and 8-K. In light of these risks and uncertainties there
can be no assurances that the forward looking statements contained
in this press release will in fact transpire or prove to be
accurate. The information in this release is provided only as of
the date of this release, and we undertake no obligation to update
any forward-looking statements contained in this release on account
of new information, future events, or otherwise, except as required
by law.
Cavitation Technologies, Inc.
Contact:
Investor Relations
Jessica Steidinger
Jessica@ctinanotech.com
Phone (818) 718-0905
Cavitation Technologies (QB) (USOTC:CVAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cavitation Technologies (QB) (USOTC:CVAT)
Historical Stock Chart
From Sep 2023 to Sep 2024